Biofrontera (BFRI) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Lipocine (LPCN) over the past year, losing 9.0% versus a loss of 38.9%. Biofrontera is the larger company by market cap ($14.4 million vs $14.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | LPCN |
|---|---|---|
| Share price | $0.97 | $1.72 |
| Market cap | $14.41M | $14.18M |
| 1-day change | +5.57% | -10.88% |
| YTD return | +61.19% | -75.97% |
| 1-year return | -9.03% | -38.92% |
| 5-year return | — | -89.95% |
| Forward P/E | 2.26 | — |
| EPS (TTM) | $-0.43 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $12.37 |
| 52-week low | $0.555 | $1.72 |
| Distance from 52-week high | -41.57% | -86.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +518.56% | +190.70% |
| Average volume | 547.45K | 1.72M |
| Shares outstanding | 14.85M | 8.24M |
| Employees | 84 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed LPCN by 29.9 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BFRI vs LPCN FAQ
Which is bigger, Biofrontera or Lipocine?
Biofrontera (BFRI) is larger, with a market capitalization of $14.41M compared with $14.18M for Lipocine (LPCN).
Which stock has performed better over the past year, BFRI or LPCN?
BFRI returned -9.03% over the past 12 months, compared with -38.92% for LPCN (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.